(Q37786355)

23 August 2017

title

Mechanisms of resistance to anti-human epidermal growth factor receptor 2 agents in breast cancer (English)

1 reference

23 August 2017

Mechanisms of resistance to anti‐human epidermal growth factor receptor 2 agents in breast cancer (English)

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01711.X

9 July 2024

1 reference

Toru Mukohara

1

1 reference

23 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20825420

9 July 2024

publication date

6 September 2010

1 reference

full work available at URL

23 August 2017

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1349-7006.2010.01711.x

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01711.X

https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1349-7006.2010.01711.x

9 July 2024

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01711.X

9 July 2024

1 reference

23 August 2017

volume

102

1 reference

23 August 2017

issue

1

1 reference

23 August 2017

page(s)

1-8

1 reference

HER2-targeting antibodies modulate the cyclin-dependent kinase inhibitor p27Kip1 via multiple signaling pathways

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01711.X

A truncated intracellular HER2/neu receptor produced by alternative RNA processing affects growth of human carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01711.X

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1126/SCIENCE.1141478

Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1158/0008-5472.CAN-08-1776

ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics

1

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01711.X

Global cancer statistics, 2002

9 July 2024

2

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01711.X

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

9 July 2024

3

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01711.X

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

9 July 2024

4

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01711.X

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

9 July 2024

5

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01711.X

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

9 July 2024

6

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01711.X

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

9 July 2024

7

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01711.X

Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer

9 July 2024

8

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01711.X

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

9 July 2024

9

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01711.X

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

9 July 2024

10

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01711.X

Transformation of NIH 3T3 cells by HER3 or HER4 receptors requires the presence of HER1 or HER2

9 July 2024

13

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01711.X

The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin

9 July 2024

14

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01711.X

Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas

9 July 2024

15

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01711.X

HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells.

9 July 2024

16

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01711.X

The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation

9 July 2024

18

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01711.X

Biologic and therapeutic role of HER2 in cancer

9 July 2024

19

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01711.X

The basic biology of HER2.

9 July 2024

20

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01711.X

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941

9 July 2024

21

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01711.X

A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy

9 July 2024

22

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01711.X

ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency

9 July 2024

24

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01711.X

Enhancement of the p27Kip1-mediated antiproliferative effect of trastuzumab (Herceptin) on HER2-overexpressing tumor cells

9 July 2024

26

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01711.X

Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer

9 July 2024

27

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01711.X

ERBB receptors and cancer: the complexity of targeted inhibitors

9 July 2024

28

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01711.X

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

9 July 2024

29

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01711.X

Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2

9 July 2024

30

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01711.X

Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016.

9 July 2024

32

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01711.X

Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.

9 July 2024

33

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01711.X

Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).

9 July 2024

36

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01711.X

Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells

9 July 2024

37

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01711.X

Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells

9 July 2024

38

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01711.X

Insulin-like growth factor-1 receptor (IGF-1R) expression does not predict for resistance to trastuzumab-based treatment in patients with Her-2/neu overexpressing metastatic breast cancer

9 July 2024

39

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01711.X

Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network

9 July 2024

41

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01711.X

Quantitation of HER2 expression or HER2:HER2 dimers and differential survival in a cohort of metastatic breast cancer patients carefully selected for trastuzumab treatment primarily by FISH.

9 July 2024

42

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01711.X

Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancer

9 July 2024

43

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01711.X

Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells

9 July 2024

44

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01711.X

Targeting the phosphoinositide 3-kinase pathway in cancer

9 July 2024

46

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01711.X

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

9 July 2024

47

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01711.X

High frequency of mutations of the PIK3CA gene in human cancers

9 July 2024

48

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01711.X

PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma

9 July 2024

49

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01711.X

Mutation of the PIK3CA gene in ovarian and breast cancer

9 July 2024

50

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01711.X

PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas.

9 July 2024

51

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01711.X

Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit

9 July 2024

52

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01711.X

The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations

9 July 2024

53

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01711.X

Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells

9 July 2024

54

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01711.X

Rare cancer-specific mutations in PIK3CA show gain of function

9 July 2024

55

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01711.X

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

9 July 2024

56

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01711.X

Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines

9 July 2024

57

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01711.X

P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells.

9 July 2024

58

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01711.X

Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma

9 July 2024

59

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01711.X

Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.

9 July 2024

60

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01711.X

A quantitative analysis of kinase inhibitor selectivity

9 July 2024

62

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01711.X

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells

9 July 2024

63

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01711.X

Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells

9 July 2024

64

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01711.X

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

9 July 2024

65

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01711.X

HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors

9 July 2024

66

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01711.X

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer

9 July 2024

68

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01711.X

Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.

9 July 2024

69

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01711.X

Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers

9 July 2024

70

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01711.X

A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer

9 July 2024

71

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01711.X

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

9 July 2024

72

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01711.X

Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy

9 July 2024

73

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01711.X

PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation

9 July 2024

76

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01711.X

Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling

9 July 2024

77

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01711.X

Vaccination against the HER-2/neu oncogenic protein

9 July 2024

78

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01711.X

Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.

9 July 2024

79

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01711.X

Ertumaxomab: a trifunctional antibody for breast cancer treatment

9 July 2024

80

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01711.X

Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer

9 July 2024

81

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01711.X

A nonfucosylated anti-HER2 antibody augments antibody-dependent cellular cytotoxicity in breast cancer patients

9 July 2024

82

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01711.X

Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer

9 July 2024

83

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01711.X

9 July 2024

Identifiers

1 reference

23 August 2017

1 reference